// App-Quantinova.ai

187 : ASN0007, a potent ERK1/2 inhibitor with strong antitumor activity in multiple RAS mutant models

Researchers

Presenter

  • Sanjeeva P. Reddy

Principal Investigators

  • Dhanalakshmi Sivanandhan

  • Raghava Reddy Kethiri

  • Sreekala Nair

  • Purushottam Dewang

  • Mohd Zainuddin

  • Krishnakumar Vaithilingam

  • Roger A. Smith

  • Sandeep Gupta

  • Scott K. Thompson

Medical Centers

  • Asana Biosciences LLC, Bridgewater, NJ

  • Jubilant Biosys Ltd., Bangalore, India

Locations

  • United States

  • India

Companies

  • Jubilant Biosys Limi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase 1

  • Mitogen-activated protein kinase 3

  • B-Raf proto-oncogene, serine/threonine kinase

  • Phosphorylated S-6 ribosomal protein

  • GTPase Nras

  • HRas Proto-Oncogene, GTPase

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Ravoxertinib

  • L-Tyrosine

  • Ulixertinib

  • ASN-007

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved